Novel Diagnostic Methods for Imaging Amyloid Beta in the eye in association with alzheimer's disease

阿尔茨海默病（AD）没有治愈方法，也没有广泛可用的早期检测方法。只有死后才能确诊。阿尔茨海默病对个人健康有很大的负面影响，给社会带来巨大的成本。早期诊断和改善疾病追踪可导致更早和更好的治疗。淀粉样蛋白在阿尔茨海默症早期在大脑中形成沉积物。我们将开发一种更简单的方法来成像眼睛后部活神经组织中的β淀粉样蛋白沉积。坎贝尔的研究小组已经证明，这些沉积物应该足够大，可以在眼睛的图像中检测到。然后，它们可以用来诊断和监测阿尔茨海默病的恶化阶段。我们将探讨视网膜中的β淀粉样蛋白与AD严重程度之间的关系。视网膜中的淀粉样蛋白沉积将在死亡后进行评估。我们将描述视网膜沉积物的位置、密度、大小和形状。在一项单独的UBC研究中，阿尔茨海默病的阶段将在临床死亡前进行测量。他们的

There is no cure and no early detection method broadly available for Alzheimer's disease (AD). Definite diagnosis is only after death. AD has a large negative impact on individual health and an enormous cost to society. Early diagnosis and improved disease tracking lead to earlier and better treatment. Amyloid beta forms deposits in the brain early in AD. We will develop a simpler method to image amyloid beta deposits in the living neural tissue at the back of the eye. Campbell's group has shown that these deposits should be large enough to be detected in images of the eye. They could then be used to diagnose and monitor the worsening stages of AD. We will explore the association between amyloid beta in the retina and the severity of AD. Amyloid beta deposits in retinas will be assessed after death. We will characterize the location, density, size and shape of retinal deposits. In a separate UBC study, the stage of AD will be measured in the clinic before death. Their